×
About 308 results

ALLMedicine™ Prurigo Nodularis Center

Research & Reviews  105 results

Diagnosis of Primary Cutaneous Amyloidosis by Rapid 4,6-Diamidino-2-Phenylindole Staining.
https://doi.org/10.1159/000518082
Dermatology (Basel, Switzerland); Chen J, Yang H et. al.

Sep 14th, 2021 - Quick and accurate diagnosis of primary cutaneous amyloidosis (PCA) may be difficult because its symptoms are often subtle and nonspecific. We sought to review the literature on the roles of various staining methods in the diagnosis of amyloidosis...

Interleukin 36 expression in psoriasis variants and other dermatologic diseases with ps...
https://doi.org/10.1111/cup.14115
Journal of Cutaneous Pathology; Aquino TM, Calvarido MG et. al.

Aug 5th, 2021 - Elevated epidermal interleukin (IL)-36 expression distinguishes psoriasis from eczematous dermatitis, but other psoriasiform dermatitides (PDs) have not been thoroughly investigated for IL-36 expression. In this study, we assess the IL-36 staining...

New-Onset Psoriasis Developing in Atopic Patient With Prurigo Nodularis After Treatment...
https://doi.org/10.1097/DER.0000000000000740
Dermatitis : Contact, Atopic, Occupational, Drug; Russo F, Provvidenziale L et. al.

Jul 27th, 2021 - New-Onset Psoriasis Developing in Atopic Patient With Prurigo Nodularis After Treatment With Dupilumab.|2021|Russo F,Provvidenziale L,Bruzziches F,Fiorani D,Santi F,|

Cognitive Impairment in Inpatients with Prurigo Nodularis and Psychiatric Comorbidities.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8296039
International Journal of Environmental Research and Publi... Lanza G, Cosentino FII et. al.

Jul 3rd, 2021 - Prurigo nodularis (PN) is a chronic refractory itchy dermatosis. Although psychiatric comorbidity is known, research in cognitive impairment is lacking. We evaluated the occurrence and types of cognitive impairment in a series of inpatients with P...

The clinical effectiveness and safety of traditional Chinese medicine uremic clearance ...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8238327
Medicine Bai YF, Wang CL et. al.

Jun 24th, 2021 - Skin pruritus is a common complication in patients with uremia. When the hemodialysis time of patients is extended, and the probability of skin pruritus is greater. Patients often have the symptoms of skin pruritus intolerable, affecting the norma...

see more →

News  18 results

Study Enhances Understanding of 'Tremendously Understudied' Prurigo Nodularis
https://www.medscape.com/viewarticle/949495

Apr 19th, 2021 - Patients with prurigo nodularis tend to make a greater number of visits to health care specialists and are burdened by a greater number of medical comorbidities, compared with age-matched controls, as well those with atopic dermatitis and psoriasi...

Nemolizumab tames itching in prurigo nodularis patients in phase 2 study
https://www.mdedge.com/dermatology/article/217918/medical-dermatology/nemolizumab-tames-itching-prurigo-nodularis-patients?channel=39212
Heidi Splete

Feb 26th, 2020 - Adults with moderate to severe prurigo nodularis who were treated with the investigational drug nemolizumab showed significant improvement in itching, compared with patients treated with placebo, according to data from a phase 2 trial of 70 patien.

Monoclonal Antibody Provides Itch Relief for Prurigo Nodularis
https://www.medscape.com/viewarticle/925465

Feb 21st, 2020 - NEW YORK (Reuters Health) - An experimental treatment for prurigo nodularis (PN) can reduce itching by 53% over four weeks, according to a phase-2 test of subcutaneous nemolizumab. The reduction was only 20% with placebo therapy. However, the impr...

Monoclonal Antibody Provides Itch Relief for Prurigo Nodularis
https://www.staging.medscape.com/viewarticle/925465

Feb 21st, 2020 - NEW YORK (Reuters Health) - An experimental treatment for prurigo nodularis (PN) can reduce itching by 53% over four weeks, according to a phase-2 test of subcutaneous nemolizumab. The reduction was only 20% with placebo therapy. However, the impr...

Rapid improvement seen with nemolizumab for prurigo nodularis in phase 2b study
https://www.mdedge.com/dermatology/article/211733/medical-dermatology/rapid-improvement-seen-nemolizumab-prurigo-nodularis?channel=39313
Bruce Jancin

Nov 6th, 2019 - MADRID – Nemolizumab, an investigational humanized monoclonal antibody targeting the interleukin-31 receptor alpha subunit, achieved rapid and clinically meaningful improvement in both itch and skin lesions of severe prurigo nodularis in a phase 2.

see more →